Market Closed -
NSE India S.E.
03:01:55 2024-05-18 EDT
|
5-day change
|
1st Jan Change
|
352
INR
|
+1.85%
|
|
-0.83%
|
-12.01%
|
Fiscal Period: Maart |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
652.2
|
739.1
|
747.3
|
1,766
|
2,313
|
3,819
|
Enterprise Value (EV)
1 |
794
|
852.9
|
911.3
|
2,192
|
3,171
|
4,976
|
P/E ratio
|
23.3
x
|
10.5
x
|
7.77
x
|
16
x
|
15.2
x
|
29.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.22
x
|
1.07
x
|
0.89
x
|
1.85
x
|
1.79
x
|
2.85
x
|
EV / Revenue
|
1.49
x
|
1.24
x
|
1.09
x
|
2.3
x
|
2.46
x
|
3.71
x
|
EV / EBITDA
|
6.14
x
|
4.87
x
|
4.41
x
|
9.45
x
|
10.7
x
|
14.6
x
|
EV / FCF
|
-26.7
x
|
-7.53
x
|
94.9
x
|
-17.2
x
|
-4.17
x
|
-6.77
x
|
FCF Yield
|
-3.74%
|
-13.3%
|
1.05%
|
-5.81%
|
-24%
|
-14.8%
|
Price to Book
|
1.41
x
|
1.03
x
|
0.92
x
|
1.79
x
|
1.82
x
|
2.2
x
|
Nbr of stocks (in thousands)
|
10,961
|
14,961
|
14,961
|
15,618
|
17,118
|
19,040
|
Reference price
2 |
59.50
|
49.40
|
49.95
|
113.1
|
135.2
|
200.6
|
Announcement Date
|
9/20/18
|
8/16/19
|
8/22/20
|
8/14/21
|
8/22/22
|
8/24/23
|
Fiscal Period: Maart |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
534.2
|
688.1
|
839.1
|
953.1
|
1,291
|
1,342
|
EBITDA
1 |
129.3
|
175
|
206.8
|
231.8
|
295
|
341
|
EBIT
1 |
85.21
|
114.6
|
136
|
151.3
|
205.6
|
191.2
|
Operating Margin
|
15.95%
|
16.65%
|
16.21%
|
15.87%
|
15.93%
|
14.25%
|
Earnings before Tax (EBT)
1 |
61.09
|
97.19
|
122.3
|
132.3
|
189.3
|
169.9
|
Net income
1 |
38.15
|
70.11
|
96.23
|
106.8
|
151.8
|
127.6
|
Net margin
|
7.14%
|
10.19%
|
11.47%
|
11.21%
|
11.76%
|
9.51%
|
EPS
2 |
2.550
|
4.686
|
6.432
|
7.086
|
8.902
|
6.862
|
Free Cash Flow
1 |
-29.73
|
-113.3
|
9.601
|
-127.4
|
-760.5
|
-735.2
|
FCF margin
|
-5.57%
|
-16.47%
|
1.14%
|
-13.37%
|
-58.9%
|
-54.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
4.64%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
9.98%
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/20/18
|
8/16/19
|
8/22/20
|
8/14/21
|
8/22/22
|
8/24/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
142
|
114
|
164
|
425
|
857
|
1,157
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.097
x
|
0.6508
x
|
0.7929
x
|
1.834
x
|
2.906
x
|
3.391
x
|
Free Cash Flow
1 |
-29.7
|
-113
|
9.6
|
-127
|
-760
|
-735
|
ROE (net income / shareholders' equity)
|
8.77%
|
11.4%
|
12.6%
|
11.9%
|
13.4%
|
8.48%
|
ROA (Net income/ Total Assets)
|
7.02%
|
7.97%
|
8%
|
6.46%
|
5.77%
|
3.96%
|
Assets
1 |
543.3
|
880.1
|
1,203
|
1,654
|
2,631
|
3,225
|
Book Value Per Share
2 |
42.20
|
47.90
|
54.40
|
63.00
|
74.50
|
91.00
|
Cash Flow per Share
2 |
0.3000
|
0.2500
|
0.2000
|
0.0500
|
0.0200
|
0.0500
|
Capex
1 |
88.1
|
249
|
133
|
355
|
975
|
822
|
Capex / Sales
|
16.49%
|
36.2%
|
15.86%
|
37.29%
|
75.54%
|
61.25%
|
Announcement Date
|
9/20/18
|
8/16/19
|
8/22/20
|
8/14/21
|
8/22/22
|
8/24/23
|
|
1st Jan change
|
Capi.
|
---|
| -12.01% | 80.46M | | +15.58% | 79.03B | | +9.87% | 8.96B | | -10.76% | 5.19B | | +54.31% | 4.77B | | +11.19% | 4.26B | | -22.37% | 2.37B | | +12.49% | 2.3B | | -30.09% | 2.21B | | +20.63% | 2.17B |
Specialty & Advanced Pharmaceuticals
|